Curamib-3.5 (Bortezomib Vials) 3.5mg

Curamib-3.5 (Bortezomib 3.5mg) is a prescription medication in vial form, used for certain types of cancer treatment. It belongs to the proteasome inhibitor class and is stored at ambient temperature. This product is manufactured in India and is intended for professional healthcare use.

Strength

3.5mg

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Mediclone Health Care Pvt Ld

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Curamib-3.5 (Bortezomib 3.5mg) is primarily used to treat multiple myeloma and mantle cell lymphoma. It works by interfering with the growth of cancer cells, slowing their spread in the body. This medication is often prescribed when other treatments have not been effective. Patients may wonder, what is bortezomib used for in cancer therapy?

Side Effects

Curamib-3.5 may cause temporary effects such as fatigue, nausea, or reduced appetite as the body adjusts to treatment. Some individuals experience mild pain or redness at the injection site. These effects are generally short-lived and vary between patients. Always report persistent or severe reactions to a healthcare provider.

Precautions & Warnings

Store Curamib-3.5 at room temperature away from moisture and heat. Keep out of reach of children and pets. Do not use if the vial is damaged or the solution appears cloudy. Handle with care to avoid accidental spills or contamination. Always follow healthcare provider instructions for safe disposal.

Avoid Interactions

Curamib-3.5 may interact with other medications, including certain blood pressure drugs, diabetes treatments, and supplements like St. John’s Wort. Alcohol and grapefruit products may also affect how bortezomib works. Always inform your doctor about all medications and supplements you are taking before starting treatment.

Frequently Asked Questions

Bortezomib is primarily used to treat multiple myeloma and mantle cell lymphoma.

Curamib-3.5 is administered by a healthcare professional via injection.

Common side effects may include fatigue, nausea, or pain at the injection site.

Bortezomib is a prescription medication and should only be obtained through licensed pharmacies.

Consult your healthcare provider before using bortezomib if you are pregnant or breastfeeding.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.